Pfizer’s “Buy” Rating Reaffirmed at TheStreet (PFE)
Pfizer (NYSE:PFE)‘s stock had its “buy” rating restated by equities research analysts at TheStreet in a research note issued to investors on Monday, Stock Ratings Network reports.
The analysts wrote, “Pfizer (PFE) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Shares of Pfizer (NYSE:PFE) opened at 31.325 on Monday. Pfizer has a 52 week low of $26.79 and a 52 week high of $32.50. The stock has a 50-day moving average of $30.61 and a 200-day moving average of $29.93. The company has a market cap of $203.0 billion and a P/E ratio of 9.51.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Monday, January 27th. The company reported $0.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.52 by $0.04. The company had revenue of $13.56 billion for the quarter, compared to the consensus estimate of $13.35 billion. During the same quarter in the prior year, the company posted $0.47 earnings per share. The company’s quarterly revenue was down 2.4% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.27 earnings per share for the current fiscal year.
PFE has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Pfizer in a research note to investors on Wednesday, January 29th. They now have a $32.00 price target on the stock. Separately, analysts at Argus reiterated a “buy” rating on shares of Pfizer in a research note to investors on Wednesday, January 29th. They now have a $35.00 price target on the stock. Finally, analysts at Cowen and Company downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating in a research note to investors on Friday, January 10th. They now have a $34.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $31.97.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.